MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
AssigneeEmergex Vaccines Holding Ltd.
InventorRamila Philip
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
Claims8
A pharmaceutical composition comprising at least one peptide consisting of 8 to about 30 amino acid residues and comprising the amino acid sequence of SEQ ID NO:
- 2, wherein said peptide can bind to class I MHC molecules from A2 and A24 supertypes, or can be processed to bind to class I MHC molecules from A2 and A24 supertypes, and activate a T lymphocyte response and wherein the peptide is in the form of a pharmaceutically acceptable salt.
A method for vaccinating and treating a subject for HBV infection, said subject comprising infected cells expressing any class I MHC molecule, comprising administering to said subject a pharmaceutical composition in an amount sufficient to induce a CTL response to said infected cells, wherein said pharmaceutical composition comprises:
- a. at least one peptide consisting of 8 to about 30 amino acid residues and comprising the amino acid sequence of SEQ ID NO:
- 2;
- or
- b. at least one peptide consisting of 8 to about 30 amino acid residues and comprising an amino acid sequence that differs from SEQ ID NO 2 by no more than one amino acid, wherein said one amino acid difference is the result of a conservative amino acid substitution
- wherein said peptide can bind to class 1 MHC;
- molecules from A2 and A24 supertypes, or can be processed to bind to class 1 MHC molecules from A2 and A24 supertypes, and activate a T lymphocyte response and wherein the peptide is in the form of a pharmaceutically acceptable salt.
A method for vaccinating humans against HBV infection using a pharmaceutical composition comprising:
- a. at least one peptide consisting of 8 to about 30 amino acid residues and comprising the amino acid sequence of SEQ ID NO:
- 2;
- or
- b. at least one peptide consisting of 8 to about 30 amino acid residues and comprising an amino acid sequence that differs from SEQ ID NO:
- 2 by no more than one amino acid, wherein said one amino acid difference is the result of a conservative amino acid substitution;
- wherein said peptide can bind to class 1 MHC molecules from A2 and A24 supertypes, or can be processed to bind to class 1 MHC molecules from A2 and A24 supertypes, and activate a T lymphocyte response and wherein the peptide is in the form of a pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.